Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial

References

• Chesi M, Nardini E, Brents LA, . Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16:260–264.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Maxwell CA, Taylor BJ, . Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood 2005;105:4060–4069.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Reiman T, Maxwell CA, . In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003;101:1520–1529.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD Jr, Zhan F, Burington BE, . A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276–2284.
   PubMed Web of Science ®Google Scholar
• Zhan F, Hardin J, Kordsmeier B, . Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745–1757.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Blood E, Rue M, . Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569–4575.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi XY, Samiee S, . Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant 2005;36:793–796.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, . Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837–2840.
   PubMed Web of Science ®Google Scholar
• Moreau P, Attal M, Garban F, . Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 2007;21:2020–2024.
   PubMed Web of Science ®Google Scholar
• Jaksic W, Trudel S, Chang H, . Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005;23: 7069–7073.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Leyvraz S, . Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289–3294.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Barlogie B, Bataille R, . Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64: 1546–1558.
   PubMedGoogle Scholar
• Morgan GJ, Davies FE, Gregory WM, . Thalidomide maintenance significantly improves progression-free survival (PFS) and overall survival (OS) of myeloma patients when effective relapse treatments are used: MRC Myeloma IX results. Blood 2010;116(Suppl. 1): Abstract 623.
   Google Scholar
• Barlogie B, Tricot G, Anaissie E, . Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021–1030.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Leleu X, Roussel M, . Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010;28:4630–4634.
   PubMed Web of Science ®Google Scholar
• Chang H, Trieu Y, Qi X, . Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007;31:779–782.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H, . Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621–4629.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, . Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–917.
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Jayabalan DS, Christos PJ, . BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008;111: 1101–1109.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Falco P, Corradini P, . Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459–4465.
   PubMed Web of Science ®Google Scholar
• Reece D, Song KW, Fu T, . Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009;114:522–525.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Caillot D, Marit G, . Long-term maintenance with lenalidomide improves progression free survival in myeloma patients with high-risk cytogenetics: an IFM study. Blood 2010;116(Suppl. 1): Abstract 1944.
   Google Scholar
• Avet-Loiseau H, Attal M, Moreau P, . Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489–3495.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Bergsagel PL, Greipp PR, . A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007;21:529–534.
   PubMed Web of Science ®Google Scholar
• Spencer A, Prince HM, Roberts AW, . Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27:1788–1793.
   PubMed Web of Science ®Google Scholar
• Compagno M, Mantoan B, Astolfi M, Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma. Methods Mol Med 2005;113:145–163.
   PubMedGoogle Scholar
• Malgeri U, Baldini L, Perfetti V, . Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res 2000;60:4058–4061.
   PubMed Web of Science ®Google Scholar
• Chang H, Sloan S, Li D, . The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004;125:64–68.
   PubMed Web of Science ®Google Scholar
• Moreau P, Facon T, Leleu X, . Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002;100:1579–1583.
   PubMed Web of Science ®Google Scholar
• Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139–149.
   PubMed Web of Science ®Google Scholar
• Johnson DE, Lee PL, Lu J, . Diverse forms of a receptor for acidic and basic fibroblast growth factors. Mol Cell Biol 1990;10:4728–4736.
   PubMed Web of Science ®Google Scholar
• Lee PL, Johnson DE, Cousens LS, . Purification and complementary DNA cloning of a receptor for basic fibroblast growth factor. Science 1989;245:57–60.
   PubMed Web of Science ®Google Scholar
• Santra M, Zhan F, Tian E, . A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 2003;101:2374–2376.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Opat SS, Taouk Y, . Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. Clin Cancer Res 2009;15:714–722.
   PubMed Web of Science ®Google Scholar
• Chesi M, Bergsagel PL, Kuehl WM. The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression. Curr Opin Hematol 2002;9:288–293.
   PubMed Web of Science ®Google Scholar
• Vatsveen TK, Brenne AT, Dai HY, . FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14). Eur J Haematol 2009;83:471–476.
   PubMed Web of Science ®Google Scholar
• Quintero-Rivera F, El-Sabbagh Badr R, Rao PN. FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma. Cancer Genet Cytogenet 2009;195:92–93.
   PubMed Web of Science ®Google Scholar
• Jang JH. Reciprocal relationship in gene expression between FGFR1 and FGFR3: implication for tumorigenesis. Oncogene 2005;24:945–948.
   PubMed Web of Science ®Google Scholar
• Plowright EE, Li Z, Bergsagel PL, . Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000;95:992–998.
   PubMed Web of Science ®Google Scholar
• Bisping G, Wenning D, Kropff M, . Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma. Clin Cancer Res 2009;15:520–531.
   PubMed Web of Science ®Google Scholar
• Chen J, Lee BH, Williams IR, . FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 2005;24:8259–8267.
   PubMed Web of Science ®Google Scholar
• Hadari Y, Schlessinger J. FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. J Clin Invest 2009;119:1077–1079.
   PubMed Web of Science ®Google Scholar
• Trudel S, Stewart AK, Rom E, . The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006;107:4039–4046.
   PubMed Web of Science ®Google Scholar